Finke, J; Bethge, WA; Schmoor, C et al.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.Lancet Oncol. Bd. 10. H. 9. 2009 S. 855-64
Gillissen, A; Glaab, T; Lewis, M et al.
Statistical analysis of chronic obstructive pulmonary disease exacerbations in clinical studies: expectations and limitations.J Physiol Pharmacol. Bd. 60 Suppl 5. 2009 S. 7-11
Weber, M; Claus, M; Münster, E et al.
Sterben in Rheinland-Pfalz - Bedürfnisse und persönliche Erfahrungen von AngehörigenZeitschrift für Palliativmedizin CD. 2009 S. 36
Kuemmel, A; Single, K; Bittinger, F et al.
TA-MUC1 epitope in non-small cell lung cancer.Lung Cancer. Bd. 63. H. 1. 2009 S. 98-105
Muller, P; Distler, E; Meyer, RG et al.
Targeting the programmed death (PD)-1/PD igand 1 pathway to induce peripheral tolerance in allograft recipientsBONE MARROW TRANSPLANTATION. Bd. 43. 2009 S. S302-S302
Naumann, SC; Roos, WP; Jost, E et al.
Temozolomide cells: response related to MGMT, MMR, DSBs, and p53Br J Cancer. Bd. 100. H. 2. 2009 S. 322-33
Hess, G; Romaguera, J; Herbrecht, R et al.
TEMSIROLIMUS FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: SUPPORTIVE EFFICACY ANALYSES FROM THE PHASE 3 STUDYHAEMATOLOGICA-THE HEMATOLOGY JOURNAL. Bd. 94. 2009 S. 391-392
Hess, G; Smith, SM; Berkenblit, A et al.
Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypesSemin Oncol. Bd. S3. 2009 S. S37-45
Buske, C; Hoster, E; Dreyling, M et al.
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).Leukemia. Bd. 23. H. 1. 2009 S. 153-61
Jansen, NW; Roosendaal, G; Lundin, B et al.
The combination of the biomarkers urinary C-terminal telopeptide of type II collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy.Arthritis Rheum. Bd. 60. H. 1. 2009 S. 290-8